These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 28975284)

  • 1. Urine Drug Screens to Monitor Opioid Use for Managing Chronic Pain.
    Haymond S; Nagpal G; Heiman H
    JAMA; 2017 Sep; 318(11):1061-1062. PubMed ID: 28975284
    [No Abstract]   [Full Text] [Related]  

  • 2. How to set boundaries with chronic pain patients.
    Cosio D
    J Fam Pract; 2014 Mar; 63(3 Suppl):S3-8. PubMed ID: 24701609
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A leader in the field...
    DeVito RA
    J Opioid Manag; 2015; 11(1):6. PubMed ID: 25881374
    [No Abstract]   [Full Text] [Related]  

  • 4. Sensitivity of an opiate immunoassay for detecting hydrocodone and hydromorphone in urine from a clinical population: analysis of subthreshold results.
    Bertholf RL; Johannsen LM; Reisfield GM
    J Anal Toxicol; 2015; 39(1):24-8. PubMed ID: 25288720
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunoassay in healthcare testing applications.
    DePriest AZ; Black DL; Robert TA
    J Opioid Manag; 2015; 11(1):13-25. PubMed ID: 25750161
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Six-month, open-label study of hydrocodone extended release formulated with abuse-deterrence technology: Safety, maintenance of analgesia, and abuse potential.
    Hale ME; Ma Y; Malamut R
    J Opioid Manag; 2016; 12(2):139-47. PubMed ID: 27194199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Drug testing and adherence monitoring in pain management: Oral fluid testing.
    Moore C
    J Opioid Manag; 2015; 11(1):69-75. PubMed ID: 25750167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of a hydrocodone extended-release tablet formulated with abuse-deterrence technology in patients with moderate-to-severe chronic low back pain.
    Hale ME; Zimmerman TR; Eyal E; Malamut R
    J Opioid Manag; 2015; 11(6):507-18. PubMed ID: 26728648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Does therapeutic use of tapentadol cause false-positive urine screens for methadone or opiates?
    Mullins ME; Hock K; Scott MG
    Clin Toxicol (Phila); 2015 Jun; 53(5):493-4. PubMed ID: 25951899
    [No Abstract]   [Full Text] [Related]  

  • 10. The clinical impact of a false-positive urine cocaine screening result on a patient's pain management.
    Kim JA; Ptolemy AS; Melanson SE; Janfaza DR; Ross EL
    Pain Med; 2015 Jun; 16(6):1073-6. PubMed ID: 24138673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hydrocodone bitartrate for chronic pain.
    Manchikanti L; Atluri S; Kaye AM; Kaye AD
    Drugs Today (Barc); 2015 Jul; 51(7):415-27. PubMed ID: 26261844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A critical assessment of opioid treatment adherence using urine drug testing in chronic pain management.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):124-31. PubMed ID: 22104461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and safety of once-daily, extended-release hydrocodone in individuals previously receiving hydrocodone/acetaminophen combination therapy for chronic pain.
    Bartoli A; Michna E; He E; Wen W
    Postgrad Med; 2015 Jan; 127(1):5-12. PubMed ID: 25526227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relationship between the concentration of hydrocodone and its conversion to hydromorphone in chronic pain patients using urinary excretion data.
    Barakat NH; Atayee RS; Best BM; Pesce AJ
    J Anal Toxicol; 2012 May; 36(4):257-64. PubMed ID: 22511700
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hysingla® ER, a once-daily, single-entity hydrocodone with abuse-deterrent properties in treating chronic nonmalignant and nonneuropathic pain in patients with osteoarthritis.
    Taber L; Baldridge S; He E; Ripa SR
    Postgrad Med; 2017 Jan; 129(1):133-139. PubMed ID: 27983881
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the Ototoxicity Potential of Once-Daily, Single-Entity Hydrocodone in Patients with Chronic Pain: Results of Two Phase-3 Clinical Studies.
    Campbell K; Kutz JW; Shoup A; Wen W; Lynch SY; He E; Ripa SR
    Pain Physician; 2017; 20(1):E183-E193. PubMed ID: 28072811
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine Spiking in a Pain Medicine Clinic: An Attempt to Simulate Adherence.
    Lee D; Bazydlo LA; Reisfield GM; Goldberger BA
    Pain Med; 2015 Jul; 16(7):1449-51. PubMed ID: 25522892
    [No Abstract]   [Full Text] [Related]  

  • 18. A multicenter, randomized, double-blind, placebo-controlled trial to assess the efficacy and safety of single-entity, once-daily hydrocodone tablets in patients with uncontrolled moderate to severe chronic low back pain.
    Wen W; Sitar S; Lynch SY; He E; Ripa SR
    Expert Opin Pharmacother; 2015; 16(11):1593-606. PubMed ID: 26111544
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chronic pain: reducing costs through early implementation of adherence testing and recognition of opioid misuse.
    McCarberg BH
    Postgrad Med; 2011 Nov; 123(6):132-9. PubMed ID: 22104462
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Using urine drug testing to support healthy boundaries in clinical care.
    Heit HA; Gourlay DL
    J Opioid Manag; 2015; 11(1):7-12. PubMed ID: 25750160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.